CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  More+  /  Biocon Malaysia

BIOCON MALAYSIA

Asia’s largest integrated insulin manufacturing and R&D facility

Biocon brings many significant advantages to healthcare in Malaysia through a strategic partnership with Duopharma Biotech Berhad, Malaysia’s leading pharmaceutical company. The partnership is leveraging its innovativeness and ingenuity to open up a world of possibilities for healthcare professionals and patients. Patient outcomes are improving with affordable cancer and insulin therapies. Biocon’s subsidiary – Biocon Sdn Bhd – and Duopharma Marketing Sdn Bhd boosted the supply of locally produced Insugen (recombinant human insulin). The successful launch of Basalog One (Insulin Glargine pen) as well as Zuhera (Trastuzumab) replaced the fear of disease with the hope of a better life.

null

Biocon’s subsidiary - Biocon Sdn Bhd - and Duopharma Marketing Sdn Bhd boosted the supply of locally produced Insugen (recombinant human insulin). Serving over 3,50,000 patients within Malaysia

null

Through Biocon Sdn Bhd, Biocon has set up Asia’s largest integrated insulin manufacturing and R&D facility in Malaysia, with an investment of USD 300 million. This also positions it as the largest foreign investment in biotechnology in Malaysia but more importantly, reflects Biocon’s commitment to put affordable life-changing medicines within the reach of patients across the world. Commercial operations commenced in 2016 with Biocon’s recombinant human insulin to be the first locally manufactured biosimilar product approved for sale in Malaysia. The facility also provides an opportunity to export affordable insulin therapies to other global geographies.

Commercial operations commenced in 2016 with Biocon’s recombinant human insulin to be the first locally manufactured biosimilar product approved for sale in Malaysia.

Biocon Malaysia Overview

Biocon Limited

Global Certifications

The Malaysia facility has regulatory clearances from the health authorities of the U.S. and EU.

It has received the cGMP certification from the National Pharmaceutical Control Bureau (NPCB), Malaysia.

The facility manufactures the Drug Substance for Biocon’s range of rh-insulin and insulin analogs as well as Drug Products in vials, cartridges and devices.

The rh-Insulin formulations (Brand Name: Insugen®-R, Insugen®-N and Insugen®-30/70) have been approved by the Drug Control Authority, Ministry of Health, Malaysia.

The product registrations in various emerging markets and regulated markets for rh-insulin and insulin analogs are in progress.

null

Biocon Sdn. Bhd.

No. 1, Jalan Bioteknologi 1, Kawasan Perindustrian SiLC, 79200 Iskandar Puteri, Johor, Malaysia

For more details or enquiries:

T +607-5600000
E queries.malaysia@biocon.com

Share